Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Journal: Leukemia & lymphoma
Published: June 12, 2026
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.
Journal: Blood cancer journal
Published: May 27, 2026
Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Prognostic Factors for Early Mortality Following Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Journal: American journal of hematology
Published: May 13, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.
Journal: American journal of hematology
Published: May 12, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Journal: Leukemia & lymphoma
Published: April 09, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Last Updated: 09/26/2026